# A Study of LY2409021 Formulations in Healthy Participants

> **NCT02385084** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY2409021

## Key facts

- **NCT ID:** NCT02385084
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Part B of the study no longer required due to new information on the study drug.
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02385084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02385084, "A Study of LY2409021 Formulations in Healthy Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02385084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*